Targeted Protein Degradation Patents

Targeted protein degradation (TPD) patents cover PROTAC innovations; molecular-glue innovations; E3-ligase-recruiter innovations; and ternary-complex and degrader-chemistry innovations — with IP held by degrader-focused biotechs and the pharma majors partnering/acquiring them (in a field that DESTROYS disease proteins rather than just inhibiting them, by hijacking the cell's protein-disposal machinery). WHY TARGETED PROTEIN DEGRADATION: conventional drugs INHIBIT a protein's active site — but many disease proteins have no good binding pocket ('UNDRUGGABLE'), and inhibition can be overcome by resistance; TPD instead recruits the ubiquitin-proteasome system to TAG and DEGRADE the whole target protein — reaching undruggable targets, acting catalytically (one degrader destroys many copies), and offering durable, resistance-busting effects; a transformative drug-discovery modality. MAJOR HOLDERS: ARVINAS (PROTAC pioneer, founded on Craig Crews's Yale work), KYMERA, C4 THERAPEUTICS, NURIX, MONTE ROSA and FOGHORN (molecular glues), plus pharma (Novartis, BMS/Celgene — whose IMiDs like lenalidomide are CRBN molecular glues, Genentech, Pfizer). PROTACs, molecular glues, E3-ligase recruiters, ternary complexes, and degrader chemistry are the core TPD patent domains — and novel E3 ligases, molecular glues, ternary-complex design, and oral degraders are the open whitespace.

PROTAC/bifunctional-degrader innovations; molecular-glue innovations; E3-ligase-recruiter innovations; and target-binder innovations represent core TPD patent domains — and the degrader molecule, the way it engages an E3 ligase, and what it binds are the foundational, high-value capabilities. PROTAC / BIFUNCTIONAL-DEGRADER PATENTS: a two-headed molecule — one end binds the TARGET protein, the other binds an E3 LIGASE, joined by a LINKER — bringing target and ligase together so the target is ubiquitinated and degraded (Arvinas); PROTAC composition (specific target binder + E3 ligand + linker) is core composition-of-matter IP. MOLECULAR-GLUE PATENTS: a smaller, single molecule (often more drug-like/oral) that 'GLUES' the target and an E3 ligase together by inducing/stabilizing a new protein–protein interface — including IMiDs (thalidomide/lenalidomide via CRBN) and novel glues (Monte Rosa/Foghorn); molecular-glue composition is distinctive, high-value IP (and harder to design rationally — discovery methods matter). E3-LIGASE-RECRUITER PATENTS: the ligand that HIJACKS an E3 ligase — CRBN and VHL are the workhorses, but NOVEL E3 ligases (with tissue-specific expression for selectivity) are a major frontier; E3-recruiter ligands and novel-ligase use are high-value, differentiating IP. TARGET-BINDER PATENTS: the ligand engaging the disease protein — including weak/non-inhibitory binders (degradation doesn't require blocking the active site, expanding druggable space). PROTAC composition, molecular glues, and novel E3-ligase recruiters are the highest-value molecule IP because the degrader, its E3 engagement, and the targets it unlocks are exactly what define the modality's reach.

Ternary-complex innovations; linker-chemistry innovations; degrader-selectivity/pharmacology innovations; and discovery-platform and delivery innovations represent additional TPD patent domains — and the cooperative target–degrader–E3 assembly, the linker that tunes it, and degrader-specific pharmacology are where mechanism and developability are won. TERNARY-COMPLEX PATENTS: the KEY mechanism — target, degrader, and E3 ligase form a cooperative TERNARY complex; methods designing/optimizing ternary-complex formation, cooperativity, and the induced protein–protein interface (structure-based design, cooperativity tuning) are core, distinctive IP (it's why some degraders work far better than their binding affinities predict). LINKER-CHEMISTRY PATENTS: for PROTACs, the LINKER (length/composition/rigidity/attachment) critically controls ternary-complex geometry, degradation efficiency, selectivity, and physicochemical properties; linker design is high-value, heavily-patented IP. DEGRADER-SELECTIVITY/PHARMACOLOGY PATENTS: degrader-specific advantages — CATALYTIC/sub-stoichiometric action, EVENT-DRIVEN (vs occupancy-driven) pharmacology, isoform/mutant SELECTIVITY (degrade one paralog), and 'hook effect' management; methods exploiting these are valuable. DISCOVERY-PLATFORM / DELIVERY PATENTS: degrader discovery/screening platforms (especially for molecular glues and new E3 ligases), and improving ORAL bioavailability/developability of large bifunctional molecules (a real challenge). Ternary-complex design, linker chemistry, and oral developability are the highest-value engineering IP because cooperative assembly, geometry tuning, and making big degraders into real oral drugs are exactly what separate a concept from a medicine.

Targeted protein degradation startup IP strategy must navigate Arvinas/Kymera/C4 and foundational PROTAC IP (the Crews/Yale and early ternary-complex/CRBN-VHL patents), the layered IP (target binder, E3 recruiter, linker, ternary complex, full composition), the crowded CRBN/VHL ligase space (novel E3 ligases are whitespace), the molecular-glue discovery challenge (hard to design — platform/screening IP matters), the developability hurdle (oral bioavailability of large bifunctionals), the §112 enablement/written-description bar (broad genus degrader claims get scrutinized), the heavy capital/clinical/FDA path, and a landscape where novel E3 ligases, molecular glues, ternary-complex design, linkers, and oral degraders are the durable assets; understand that CRBN/VHL PROTACs are crowded, so the durable IP is in NOVEL E3 ligases, molecular glues, ternary-complex/linker engineering, undruggable targets, and oral developability — with discovery platforms and chemistry depth often the real moat, and that drug-like properties, selectivity, and clinical efficacy matter as much as patents; identify whitespace in new ligases, glues, and oral degraders. TPD STARTUP IP STRATEGY: CRBN/VHL PROTACS ARE CROWDED — NOVEL E3 LIGASES, MOLECULAR GLUES, TERNARY/LINKER DESIGN, AND ORAL DEGRADERS ARE THE IP: patent novel E3-ligase recruiters, molecular glues, ternary-complex/linker designs, new targets, and developable oral degraders; PROTECT IN LAYERS: separate IP on the TARGET binder, the E3 RECRUITER, the LINKER, the TERNARY complex, and the FULL composition — layered estates are stronger and harder to design around; NOVEL E3 LIGASES ARE A KEY WHITESPACE: beyond CRBN/VHL, new ligases (esp. tissue-restricted for selectivity/lower tox) are high-value, differentiating IP; MOLECULAR GLUES ARE DISTINCTIVE BUT HARD TO DESIGN — PLATFORM IP MATTERS: glues are smaller/more oral but discovered more than designed — screening/discovery-platform IP and specific glue compositions are valuable; TERNARY-COMPLEX + LINKER ENGINEERING IS CORE TECHNICAL IP: cooperativity and linker geometry drive efficiency/selectivity — structure-based design methods are defensible; ORAL DEVELOPABILITY IS A REAL HURDLE AND DIFFERENTIATOR: making large bifunctionals orally bioavailable is hard — methods/compositions achieving it are valuable; MIND §112 ENABLEMENT/WRITTEN DESCRIPTION: broad degrader genus claims face enablement/written-description scrutiny — support claims with data; DISCOVERY PLATFORM/CHEMISTRY DEPTH IS OFTEN THE MOAT: degrader/glue discovery engines and medicinal-chemistry know-how (some trade-secret) drive the pipeline; DRUG-LIKE PROPERTIES/SELECTIVITY/CLINICAL MATTER AS MUCH AS PATENTS: developability, selectivity, and efficacy drive value; WHEN TO PATENT: NOVEL DEGRADER/GLUE/LIGASE/LINKER WITH MEASURED DEGRADATION DATA: file once a candidate shows measured results (target degradation potency/DC50 + selectivity + ternary-complex cooperativity + catalytic/durable effect + oral PK/developability) — measured degradation potency/selectivity, ternary cooperativity, and oral developability are the critical TPD IP metrics; KEY FTO CHECKLIST: Arvinas/Kymera/C4/Nurix PROTAC + foundational Crews/Yale + CRBN/VHL ternary-complex IP; PROTAC composition (target binder + E3 ligand + linker); molecular glue (IMiD/CRBN + novel) + discovery platform; E3-ligase recruiter (CRBN/VHL/novel ligase); ternary-complex design/cooperativity; linker chemistry (length/composition/geometry); degrader selectivity/catalytic/event-driven pharmacology; oral bioavailability/developability; §112 enablement for genus claims; FDA/clinical path.